Research
Hormonal
NN1706 treatment led to 8.2% weight loss from baseline after 10 weeks in adults with overweight/obesity.
NN1706 may be an effective treatment option for weight loss in adults with overweight or obesity.
StrongSupportsmedium confidence
NN1706 treatment led to 8.2% weight loss from baseline after 10 weeks in adults with overweight/obesity.
Why this rating
The claim is based on human participant data from a clinical trial.
Source
A once-daily GLP-1/GIP/glucagon receptor tri-agonist (NN1706) lowers body weight in rodents, monkeys and humans
Brian Finan et al. · Molecular Metabolism · 2025
otherCited 13×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →